Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Inovio Pharmaceuticals IncTrade
Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Vanguard S&P 500 ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M), while Vanguard S&P 500 ETF trades at $709.62. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOVOO
Market Cap
$78.55M
Sector
HealthBroad Market / Factor
52-Week High
$2.87$710.71
52-Week Low
$0.66$580.93
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Vanguard S&P 500 ETF

VOO, the Vanguard S&P 500 ETF, trades at $710.19, down slightly by 0.06% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is near its pivot point of $709, with immediate resistance at $711. Recent news highlights the S&P 500 at record highs, with JPMorgan raising its year-end target to 8,000, citing strong earnings and AI-driven growth, while some caution emerges from overbought signals and high valuations.

The outlook remains positive given institutional bullishness and AI tailwinds, but risks include market overvaluation, potential pullbacks from overbought conditions, and sensitivity to inflation data. Long-term investors may benefit from dollar-cost averaging, though short-term volatility warrants caution amid elevated sentiment and technical indicators signaling near-term exhaustion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.

Read more on VOO